Traws Pharma announces progress in the development of tivoxavir marboxil

Traws Pharma (TRAW) announced progress in the development of its investigational one-dose influenza investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu. “In laboratory testing, tivoxavir marboxil inhibited multiple isolates of highly pathogenic avian influenza H5N1. We evaluated the effects of drug treatment in mice exposed to human H5N1, where the virus was isolated from a dairy worker exposed to infected cattle,” said David Pauza, PhD, Chief Science Officer for Traws Pharma. “Oral treatment with tivoxavir marboxil after the virus infection resulted in complete survival and lung virus levels below the limit of quantitation. This result is highly encouraging for future clinical development of tivoxavir marboxil for treating human H5N1 influenza.” “Current topline data from our Phase I clinical trial demonstrated safety and tolerability of tivoxavir marboxil, and maintenance of drug levels in blood above the EC90 for longer than 23 days, with topline data for a higher dose still to come,” said Werner Cautreels, PhD, CEO of Traws Pharma. “In addition, the potential for tivoxavir marboxil as a treatment for H5N1 bird flu was demonstrated in an animal model.” Phase 2 study is expected to begin in 1H25.